



AMENDMENTS

In The Claims:

Please cancel claim 23 without prejudice or disclaimer and add new claims 24-32:

24. (New) A method for suppressing a sensitized T-cell, comprising administering to a subject a pharmaceutical composition comprising an antibody directed against interleukin-6 (IL-6) receptor and a pharmaceutically acceptable carrier.

25. (New) The method according to claim 24, wherein the antibody directed against IL-6 receptor is a monoclonal antibody.

26. (New) The method according to claim 25, wherein the monoclonal antibody is directed against human IL-6 receptor.

27. (New) The method according to claim 25, wherein the monoclonal antibody is directed against mouse IL-6 receptor.

28. (New) The method according to claim 26, wherein the monoclonal antibody is PM-1 antibody.

29. (New) The method according to claim 27, wherein the monoclonal antibody is MR16-1 antibody.

30. (New) The method according to claim 26, wherein the monoclonal antibody has the constant region of human antibody.

31. (New) The method according to claim 26, wherein the monoclonal antibody is a chimeric or humanized antibody directed against IL-6 receptor.



(New) The method according to claim 31, wherein the monoclonal antibody is humanised PM-1 antibody.